A rapid, low pH, nutrient stress, assay to determine the bactericidal activity of compounds against non-replicating *Mycobacterium tuberculosis*

Julie V. Early, Steven Mullen, Tanya Parish*

TB Discovery Research, Infectious Disease Research Institute, Seattle, Washington, United States of America

* tanya.parish@idri.org

Abstract

There is an urgent need for new anti-tubercular agents which can lead to a shortened treatment time by targeting persistent or non-replicating bacilli. In order to assess compound activity against non-replicating *Mycobacterium tuberculosis*, we developed a method to detect the bactericidal activity of novel compounds within 7 days. Our method uses incubation at low pH in order to induce a non-replicating state. We used a strain of *M. tuberculosis* expressing luciferase; we first confirmed the linear relationship between luminescence and viable bacteria (determined by colony forming units) under our assay conditions. We optimized the assay parameters in 96-well plates in order to achieve a reproducible assay. Our final assay used *M. tuberculosis* in phosphate-citrate buffer, pH 4.5 exposed to compounds for 7 days; viable bacteria were determined by luminescence. We recorded the minimum bactericidal concentration at pH 4.5 (MBC\textsubscript{4.5}) representing >2 logs of kill. We confirmed the utility of the assay with control compounds. The ionophores monensin, niclosamide, and carbonyl cyanide 3-chlorophenylhydrazone and the anti-tubercular drugs pretomanid and rifampicin were active, while several other drugs such as isoniazid, ethambutol, and linezolid were not.

Introduction

Tuberculosis, the most fatal disease caused by an infectious agent, caused 1.3 million deaths in 2018 [1]. Treatment requires multiple antibiotics and takes at least 6 months for drug sensitive strains and can take more than 2 years for drug-resistant strains [2]. The long treatment time is at least partly due to non-replicating populations of the causative agent, *Mycobacterium tuberculosis* [3], that are not targeted by most drugs [4]. The inclusion of pyrazinamide to the treatment regimen reduces the duration of therapy from 9 to 6 months; likely because pyrazinamide is active against non-replicating *M. tuberculosis* [5]. Therefore developing new drugs that are active against non-replicating *M. tuberculosis* with the goal to shorten therapy is of utmost importance.
Several laboratory models have been developed to identify compounds active against non-replicating *M. tuberculosis*. In the Wayne model, *M. tuberculosis* is cultured in sealed glass tubes with a limited headspace ratio; growth of the organism depletes the oxygen content of the medium within two weeks [6]. Entering this hypoxic condition prevents the bacteria from dividing further and initiates a non-replicating, non-dividing state. A high throughput adaptation of this model, the low oxygen recovery assay (LORA), has been used to screen compounds for activity against non-replicating *M. tuberculosis*. LORA includes an outgrowth period of at least 28 hours in normoxia after exposure to hypoxia for 10 days before bacterial survival is measured [7]. Models with more complex conditions have been used to screen compounds. In the multi-stress model, *M. tuberculosis* is cultured using butyrate as a carbon source at pH 5.0, 1% oxygen, and nitric oxide to induce a non-replicating state. After exposure to compounds for 3 days, bacterial survival is assessed by aerobic outgrowth for 7–10 days [8]. An alternative multi-stress model used low oxygen (5%), high CO\(_2\) (10%), low nutrients (10% Dubos medium), and acidic pH (5.0) followed by outgrowth for 9 days and measuring metabolic activity using Alamar blue [9]. A disadvantage of all of these models, is the inclusion of a recovery or outgrowth phase in which bacteria are replicating, which make the interpretation of compound activity more complicated.

More recently, the use of the streptomycin-dependent 18b strain of *M. tuberculosis* allowed the development of an assay which does not use outgrowth [10]. *M. tuberculosis* is deprived of streptomycin for 2 weeks to induce the non-replicating state, bacteria are exposed to compounds for 7 days, and bacterial survival is measured using resazurin [10]. Luciferase has also been used as a readout of bacterial viability, for example using a strain of *M. tuberculosis* expressing an inducible luciferase [11]. Bacteria are maintained in medium without a carbon source for 5 weeks, exposed to compounds for 5 days, and luciferase activity measured in lysed cells with added luciferase reagent [11].

We were interested in developing a simple assay to determine bactericidal activity against non-replicating *M. tuberculosis*, which did not require an outgrowth period, and which had an easily measured readout with the minimum of manipulations.

### Materials and methods

#### Culture

*M. tuberculosis* H37Rv was cultured in Middlebrook 7H9 medium containing 10% v/v OADC (oleic acid, albumin, dextrose, catalase) (Becton Dickinson) and 0.05% v/v Tween 80 (7H9-OADC-Tw) plus 20 μg/mL kanamycin (Sigma-Aldrich) at 37°C. A recombinant strain carrying plasmid pMV306hsp+LuxAB+G13+CDE (which constitutively expresses luciferase) was used [12, 13]. Phosphate-citrate buffer (PCB) pH 4.5 was prepared by combining 448 mL of 0.2 M dibasic sodium phosphate (Sigma-Aldrich) with 552 mL of 0.1 M citric acid (Sigma Aldrich). The pH was adjusted to pH 4.5 with 0.2 M dibasic sodium phosphate or 0.1 M citric acid solution at room temperature. Tyloxapol (Sigma-Aldrich) was added to a final concentration of 0.05% v/v; the solution was filter sterilized through a 0.22 μm filter and stored at room temperature (RT) for up to 1 month. Colony forming units (CFU) were enumerated by tenfold serial dilution and plating for colony counts on Middlebrook 7H10 medium containing 10% v/v OADC; CFUs were counted after 4 weeks incubation at 37°C.

#### Compound preparation

Compounds were purchased as powders from Sigma-Aldrich, except bedaquiline (Cellagen Technology), linezolid (Selleck Chemicals) and moxifloxacin (Fisher). Compounds were prepared in DMSO at 10 mM and stored in 70 μL aliquots at -20°C; stock solutions were thawed.
at RT overnight. Two-fold serial dilution series were prepared in 96-well polypropylene plates (Greiner) using a Biomek 3000 or 4000 (Beckman Coulter). Plates were sealed with DMSO-resistant thermal seals (Phenix) and stored at RT for up to 6 months.

**Assay plate preparation**

PCB pH 4.5 was dispensed into columns 1–11 (50 μL) and column 12 (100 μL) of sterile 96-well white flat bottom assay plates (Corning Costar) using a Multidrop Combi (Thermo). Compounds (2.04 μL) were added in columns 2–11 using a Biomek 3000 or 4000; rifampicin or DMSO was added into columns 1 and 12 respectively. The final DMSO concentration was 2%, with a typical starting concentration of 200 μM for test compounds in column 2, 100 μM of test compound in column 3, 50 μM of test compound in column 4 etc. through 0.39 μM in column 11. Assay plates were covered with sterile lids and inoculated within 3 h.

**Medium throughput assay for bacterial survival**

*M. tuberculosis* was grown to late log-phase (OD$_{590}$ 0.6–1.0), harvested and resuspended in 10 mL of PCB pH 4.5 to an OD$_{590}$ of 1.0; 50 μL of culture was dispensed into each well of columns 1–11 of the assay plates containing PCB for a final volume of 100 μL per well. Plates were incubated in this non-replicating condition with lids in sealed bags at 37˚C in a humidified incubator for 7 days. Luminescence was measured on a Synergy 2 (Biotek) plate reader with dark adjustment for 3 min at RT using a 1 sec integration time.

**Data analysis and quality control**

For each assay plate, the Z’ [14] was calculated, and the threshold value was calculated as 3 × the average signal in column 12 (background control). Quality control criteria were set as follows: average relative light units (RLU) for wells in column 12 < 2500; average RLU for wells A1-D1 (maximum kill) < 5000; average RLU for wells E1-H1 (minimum kill) > 50,000; and Z’ was ≥ 0.5. For each compound, the well with the lowest concentration of compound that had RLU below the threshold value was reported as the MBC$_{4.5}$. Based on the RLU to CFU correlation, the MBC$_{4.5}$ is equivalent to ≥ 2 logs decrease in CFU.

**Results**

We wanted to develop a rapid and simple assay for determining the bactericidal activity of compounds against *M. tuberculosis* in 96-well format. We selected low pH as the mechanism for inducing the non-replicating state since *M. tuberculosis* is likely to be exposed to acidic conditions in the host [15] and the observation that pyrazinamide shortens treatment and is active against *M. tuberculosis* under low pH conditions [3]. We had previously used standard methods to determine bacterial viability under non-replicating conditions at low pH using CFUs [16–18], but this is labor intensive and not amenable to testing large numbers of compounds.

**Luminescence is a good readout for bacterial viability**

We compared the use of fluorescence and luminescence as a reporter of bacterial viability. Our aim was to find a reporter with a good dynamic range, but in particular with a low limit of detection. We wanted to find a reporter which could reliably monitor a decrease of >2 logs of viable bacteria. We used *M. tuberculosis* constitutively expressing either a fluorescent reporter (DsRed) [19] or the bacterial lux operon [13]. The advantage of the latter is that an exogenous substrate is not required [13].
We determined the limit of detection and signal linearity for both strains as compared to OD$_{590}$. OD itself is not a useful readout, since it has a small dynamic range with a lower limit of detection of 0.01 and an upper limit of 1.0. Bacterial cultures were adjusted to OD$_{590}$ ~1.0 and ten-fold serially dilutions prepared in PCB pH 4.5 in 96-well plates (Fig 1). Both reporters demonstrated good signal and linearity over a wide range. However, the luminescence had a larger range of linearity, with a limit of detection about 2 logs lower than for fluorescence (Fig 1). The RLU to CFU correlation was also confirmed in phosphate buffered saline for the H37Rv:Luc strain (S1 Fig). Viable bacteria were measured from the starting cultures; for both H37Rv:DsRed and H37Rv:Luc an OD$_{590}$ of 1.0 was equivalent to 1.7 x 10$^9$ ± 1.1 x 10$^9$ CFU/mL; for the wild-type strain an OD$_{590}$ of 1.0 was equivalent to 2.8 x 10$^8$ ± 1.1 x 10$^8$ CFU/mL.

We tested the luciferase reporter for its ability to monitor bacterial viability for non-replicating bacteria. We cultured *M. tuberculosis* at low pH over 7 days in PCB pH 4.5 (Fig 2). The limit of detection and linearity did not change after 7 days, with the lower limit at a theoretical OD$_{590}$ of 0.005 and a linear relationship up to an OD$_{590}$ of 0.5. This gave us a usable range of 3 logs difference with a minimum detection of about 8 x10$^5$ CFU/mL. We saw a good correlation between two independent runs (Fig 2).

We optimized signal detection using the Synergy 2 plate reader; the final settings were a 3 min dark adjustment, followed by a top read of 1 sec integration. This gave us a signal to background ratio of 104 ± 7.6 (n = 3). We monitored assay variability over 21 days. *M. tuberculosis* was incubated in 96-well plates (100 μL per well) for 7–21 days. After 7 days, variability, as measured by the coefficient of variation (CV), was <20% in four independent runs (9%, 10%, 11% and 14%) which meets the criterion for intra-plate variation [20]. Incubation for 14–21 days resulted in higher variation, likely due to increased edge effects from evaporation after prolonged incubation at 37˚C (CVs of 23% at day 14 and 43% at day 21).

---

**Fig 1. Comparison of fluorescent and luminescent reporters of bacterial viability.** Recombinant *M. tuberculosis* strains were grown to late log phase and adjusted to an OD$_{590}$ of 1.0. Serial dilutions were prepared in phosphate citrate buffer in 96-well plates. RLU and relative fluorescence units (RFU) were measured using a Synergy H4 plate reader. Data are the average and standard deviation from 2 independent experiments.

https://doi.org/10.1371/journal.pone.0222970.g001
Based on our optimization, we selected the following assay parameters: H37Rv:Luc in PCB pH 4.5 for 7 days of incubation with the Synergy 2 plate reader. The starting OD$_{590}$ was 0.5 with a final assay volume of 100 μL per well and 2% final DMSO concentration using white 96-well plates.

**Luminescence is a reliable reporter of bacterial viability**

We tested the ability of the assay to determine bactericidal activity for a range of compounds. We defined bactericidal activity as a 2-log reduction in signal (RLU or CFU) over the 7 days. We set up duplicate plates for each experiment and used one set to measure RLU and the second set to determine CFUs. We tested a total of 156 samples from untreated (DMSO) and treated controls using a range of antibiotics and monensin, an ionophore (Fig 3). For each well, we determined the cutoff point which represents a 2-log reduction in viable bacteria—for RLU we set the cutoff point as 3X the background signal, for CFU it was the experimentally
determined numbers. In 87% of the samples, the two readouts gave the same result; there were a small number of discrepancies (13%). Of these, 4 wells (2.6%) were false negatives, where the RLU overestimated the viable bacteria and 17 wells (11%) where the RLU underestimated the viable bacteria. Since the false positive rate was low, we considered that this would be a useful assay to determine bactericidal activity rapidly.

Use of LOPCIDAL to determine MBCs at pH 4.5

We tested a number of known antibiotics with varied mechanisms of action and ionophores using this assay, named LOPCIDAL (low pH bactericidal) (Table 1). Compounds were tested in dose response using two-fold serial dilutions. The MBC at pH 4.5 (MBC$_{4.5}$) was determined as reported as the lowest concentration of compound with a signal below the threshold value. The threshold value was calculated as the average of 3X background for the control column wells (column 12). Data were reproducible between two experiments. This represents a 2-log reduction in viable bacteria. As expected, the ionophores niclosamide, monensin, and CCCP were active with measurable MBC$_{4.5}$s (Table 1). Pretomanid and rifampicin were also active.
under these conditions, consistent with previous results that these drugs can kill non-replicating \textit{M. tuberculosis} [21, 22]. Pyrazinamide was not active, despite the fact that we were testing at low pH. However, we were only able to test pyrazinamide up to 200 $\mu$M, and higher concentrations of pyrazinamide are required to inhibit growth, even at low pH [23]. Interestingly, the other compounds tested were not active, even known antibiotics and anti-tubercular drugs (isoniazid, bedaquiline and ethambutol). For bedaquiline and metronidazole, this may be due to short length of the assay (7 days) and that these compounds required extended time before killing is observed [24]. These data suggest that killing non-replicating bacilli at low pH may be difficult, and adds further weight to the requirement for new drugs that target bacteria in different physiological states.

### Conclusion

We have developed a rapid method to identify compounds with bactericidal activity against non-replicating \textit{M. tuberculosis} at low pH. The assay uses a luciferase reporter as a measure of bacterial viability and can provide data within 7 days. Since the assay uses a 96-well format, it is amenable to automation, can be high throughput, and does not require an outgrowth period. The reduction in time from 49 days (7 weeks) to 7 days is a substantial saving. In addition, the 96-well format allows for full dose response curves to be generated in a less labor intensive fashion. This method could be used to support lead generation programs in drug discovery, where rapid assays for structure-activity relationship studies are required.

Although this assay can be used as a rapid screen, it does not provide full determination of kill kinetics and cannot be used for longer than 7 days (due to edge effects). However, it can be used as a rapid screen to identify molecules that can be followed up in more detail. The main disadvantage of this assay is the higher starting inoculum ($>10^8$ CFU/mL), so that compounds with an inoculum-dependent effect might be missed, and that a small population of resistant mutants might be present at the outset [25]. The latter issue is tempered by the fact with the assay only requires 7 days growth, and generally resistance is not seen in outgrowth until day 14. In addition this assay is carried out under non-replicating conditions, such that resistant

| Compound        | MBC ($\mu$M) |
|-----------------|--------------|
| Pretomanid      | 12           |
| Monensin        | 50           |
| CCCP            | 3.1          |
| Bedaquiline     | $>50$        |
| Metronidazole   | $>200$       |
| Linezolid       | $>200$       |
| Pyrazinamide    | $>200$       |
| Ethambutol      | $>200$       |
| Levofloxacin    | $>200$       |
| D-Cycloserine   | $>200$       |
| Isoniazid       | $>200$       |
| Moxifloxacin    | $>200$       |
| Rifampicin      | $75 \pm 28$ (n = 21) |
| Niclosamide     | $0.22 \pm 0.080$ (n = 9) |

The MBC$_{4.5}$ was determined for each compound twice; niclosamide and rifampicin were tested multiple times and data reported as average and standard deviation.

https://doi.org/10.1371/journal.pone.0222970.t001
mutants will not grow. This assay could be used with *M. tuberculosis* strains other than H37Rv, but would require each strain to be transformed with the pMV306hsp+LuxAB+G13+CDE plasmid.

**Supporting information**

S1 Fig. We determined the CFU to RLU correlation in 4 independent experiments. Briefly, a late log-phase culture of the luciferase-expressing strain of *M. tuberculosis* was adjusted to OD$_{590}$ 1.0 in PBS-Tyloxapol. Serial dilutions were prepared and RLU and CFU determined from triplicate wells. Data are mean +/- standard deviation. RLU = relative light units. CFU = colony forming units.

(DOCX)

**Acknowledgments**

We thank Torey Alling for technical assistance. This work was funded in part by Eli Lilly and Company in support of the mission of the Lilly TB Drug Discovery Initiative and by the Bill and Melinda Gates Foundation, under grant OPP1024038.

**Author Contributions**

**Conceptualization:** Tanya Parish.

**Formal analysis:** Julie V. Early, Tanya Parish.

**Funding acquisition:** Tanya Parish.

**Investigation:** Julie V. Early, Steven Mullen.

**Methodology:** Julie V. Early, Steven Mullen.

**Resources:** Tanya Parish.

**Supervision:** Julie V. Early, Tanya Parish.

**Validation:** Julie V. Early, Steven Mullen, Tanya Parish.

**Visualization:** Julie V. Early, Steven Mullen.

**Writing – original draft:** Julie V. Early, Steven Mullen.

**Writing – review & editing:** Julie V. Early, Tanya Parish.

**References**

1. WHO. Global Tuberculosis Report 2018 2018. Available from: http://www.who.int/tb/publications/global_report/en/.

2. WHO. Guidelines for treatment of tuberculosis 2010. Available from: http://www.who.int/tb/publications/2010/9789241547833/en/.

3. Gordon SV, Parish T. Microbe Profile: Mycobacterium tuberculosis: Humanity’s deadly microbial foe. Microbiology (Reading, England). 2018; 164(4):437–9. Epub 2018/02/22. https://doi.org/10.1099/mic.0.000601 PMID: 29465344.

4. Gomez JE, McKinney JD. M. tuberculosis persistence, latency, and drug tolerance. Tuberculosis (Edinb). 2004; 84(1–2):29–44. PMID: 14670944.

5. McDermott W, Tompsett R. Activation of pyrazinamide and nicotinamide in acidic environments in vitro. American review of tuberculosis. 1954; 70(4):746–54. PMID: 13197751.

6. Wayne LG, Hayes LG. An in vitro model for sequential study of shutdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence. Infect Immun. 1996; 64(6):2062–9. PMID: 8675308; PubMed Central PMCID: PMC174037.
7. Cho SH, Warit S, Wan B, Hwang CH, Pauli GF, Franzblau SG. Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2007; 51(4):1380–5. https://doi.org/10.1128/AAC.00055-06 PMID: 17210775; PubMed Central PMCID: PMC1855511.

8. Gold B, Warrier T, Nathan C. A multi-stress model for high throughput screening against non-replicating Mycobacterium tuberculosis. Methods in molecular biology (Clifton, NJ). 2015; 1285:293–315. Epub 2015/03/18. https://doi.org/10.1007/978-1-4939-2450-9_18 PMID: 25779324.

9. Deb C, Lee CM, Dubey VS, Daniel J, Abomoelak B, Sirakova TD, et al. A novel in vitro multiple-stress dormancy model for Mycobacterium tuberculosis generates a lipid-loaded, drug-tolerant, dormant pathogen. PLoS One. 2009; 4(6):e6077. https://doi.org/10.1371/journal.pone.0006077 PMID: 19562030; PubMed Central PMCID: PMC2698117.

10. Zhang M, Sala C, Hartkoorn RC, Dhar N, Mendoza-Losana A, Cole ST. Streptomycin-starved Mycobacterium tuberculosis 18b, a drug discovery tool for latent tuberculosis. Antimicrob Agents Chemother. 2012; 56(11):5782–9. https://doi.org/10.1128/AAC.01125-12 PMID: 22926567; PubMed Central PMCID: PMC3486539.

11. Grant SS, Kawate T, Nag PP, Silvis MR, Gordon K, Stanley SA, et al. Identification of novel inhibitors of nonreplicating Mycobacterium tuberculosis using a carbon starvation model. ACS Chem Biol. 2013; 8(10):2224–34. https://doi.org/10.1021/cb4004817 PMID: 23898841; PubMed Central PMCID: PMC3864639.

12. Andreu N, Fletcher T, Krishnan N, Wiles S, Robertson BD. Rapid measurement of antituberculosis drug activity in vitro and in macrophages using bioluminescence. The Journal of antimicrobial chemotherapy. 2012; 67(2):404–14. https://doi.org/10.1093/jac/dkr472 PMID: 22102127; PubMed Central PMCID: PMC3254196.

13. Andreu N, Zelmer A, Fletcher T, Elkington PT, Ward TH, Ripoll J, et al. Optimisation of bioluminescent reporters for use with mycobacteria. PLoS One. 2010; 5(5):e10777. https://doi.org/10.1371/journal.pone.0010777 PMID: 20520722; PubMed Central PMCID: PMC2875389.

14. Zhang JH, Chung TD, Oldenburg KR. A simple statistical parameter for use in evaluation and validation of high throughput screening. Journal of biomolecular screening. 1999; 4(2):67–73. https://doi.org/10.1177/108705719900400206 PMID: 10838414.

15. Yates RM, Hermetter A, Taylor GA, Russell DG. Macrophage activation downregulates the degradative capacity of the phagosome. Traffic. 2007; 8(3):241–50. https://doi.org/10.1111/j.1600-0854.2006.00528.x PMID: 17319801.

16. Early J, Alling T. Determination of compound kill kinetics against Mycobacterium tuberculosis. Methods in molecular biology (Clifton, NJ). 2015; 1285:269–79. https://doi.org/10.1007/978-1-4939-2450-9_16 PMID: 25779322.

17. Early J, Ollinger J, Darby C, Alling T, Mullen S, Casey A, et al. Identification of Compounds with pH-Dependent Bactericidal Activity against Mycobacterium tuberculosis. ACS infectious diseases. 2019; 5(2):272–80. Epub 2018/12/07. https://doi.org/10.1021/acsinfecdis.8b00256 PMID: 30501173; PubMed Central PMCID: PMC6371205.

18. Betts JC, Lukey PT, Robb LC, McAdam RA, Duncan K. Evaluation of a nutrient starvation model of Mycobacterium tuberculosis persistence by gene and protein expression profiling. Molecular Microbiology. 2002; 43(3):717–31. https://doi.org/10.1046/j.1365-2958.2002.02779.x PMID: 11929527.

19. Carroll P, Muwanguzi-Karugaba J, Parish T. Codon-optimized DsRed fluorescent protein for use in Mycobacterium tuberculosis. BMC research notes. 2018; 11(1):685. Epub 2018/10/05. https://doi.org/10.1186/s13104-018-3798-3 PMID: 30285840; PubMed Central PMCID: PMC6176387.

20. Iversen PW, Beck B, Chen YF, Dere W, Devanarayan V, Eastwood BJ, et al. HTS Assay Validation. In: Sittampalam GS, Cossens NP, Brimacomb e K, Grossman A, Arkin M, Auld D, et al., editors. Assay Guidance Manual. Bethesda (MD): Eli Lilly & Company and the National Center for Advancing Translational Sciences; 2004.

21. Stover CK, Warrener P, VanDevanter DR, Sherman DR, Arain TM, Langhome MH, et al. A small molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature. 2000; 405(6789):962–6. Epub 2000/07/06. https://doi.org/10.1038/35016103 PMID: 10879539.

22. Iacobino A, Piccaro G, Giannoni F, Mustazzolu A, Fattorini L. Fighting tuberculosis by drugs targeting nonreplicating Mycobacterium tuberculosis bacilli. Int J Mycobacteriol. 2017; 6(3):213–21. https://doi.org/10.4103/ijmy.ijmy_85_17_85_17 PMID: 28776518.

23. Salfinger M, Heifets LB. Determination of pyrazinamide MICs for Mycobacterium tuberculosis at different pHs by the radiometric method. Antimicrobial agents and chemotherapy. 1988; 32(7):1002–4. https://doi.org/10.1128/aac.32.7.1002-4.32.7.1002-4.
24. Piccaro G, Poce G, Biava M, Giannoni F, Fattorini L. Activity of lipophilic and hydrophilic drugs against dormant and replicating Mycobacterium tuberculosis. J Antibiot (Tokyo). 2015; 68(11):711–4. https://doi.org/10.1038/ja.2015.52 PMID: 25944535.

25. (CLSI) CaLSI. Methods for Determining Bactericidal Activity of Antimicrobial Agents; Approved Guideline. Wayne, Pennsylvania: Clinical and Laboratory Standards Institute; 1999.